Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C

June 8, 2011 By Bio-Medicine.Org

PRINCETON, N.J., June 8, 2011 /PRNewswire/ — Pharmasset, Inc.
(Nasdaq:
VRUS
) announced today the addition of three treatment cohorts
to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase
inhibitor, for the treatment of chronic hepatitis C (HCV). The
rapid and consistent antiviral effects and high barrier to
resistance demonstrated with PSI-7977 to date provide the rationale
for additional exploratory regimens in this setting.  This
amendment will add one arm exploring 12 weeks of PSI-7977
monotherapy (without peginterferon and ribavirin) and two arms of
interferon-sparing therapy: one for 8 weeks of PSI-7977 plus
peginterferon and ribavirin (Peg-IFN/RBV) in patients with HCV
genotype 2 (GT2) or 3 (GT3) and one for 12 weeks of PSI-7977 plus
Peg-IFN/RBV in patients with HCV genotype 1 (GT1) prior null
responses.  

“The combination data reported at EASL demonstrated that SVRs
were achievable with two oral DAAs in the absence of peginterferon
and ribavirin,” stated Bill Symonds, PharmD, Pharmasset’s Senior
Vice President of Clinical Pharmacology and Translational Medicine,
“We continue to explore the potential for removing peginterferon
and ribavirin from the HCV treatment regimen. Given the encouraging
data we are seeing in ELECTRON, we have decided to expand the study
to investigate PSI-7977 monotherapy, as well as shorter treatment
regimens based on the promising data we reported at EASL from
PROTON.”

Pharmasset anticipates reporting results from the first four
arms of the trial (n=40) during the second half of 2011. We have
submitted a number of abstracts to the 2011 American Association
for the Study of Liver Diseases (AASLD) meeting, including data
from the ELECTRON and PROTON trials.

About the Trial

The ELECTRON trial is an exploratory study of PSI-7977 for the
treatment of chronic HCV infection. Part 1 of the trial is ev

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech